1000 Atlantic Avenue
About Alveo Technologies
Alveo is a pre-clinical stage medical diagnostics company that is creating a new ecosystem for the detection of diseases by breaking down the barriers between consumers, patients, donors and conventional healthcare systems.
Founders: Ron Chiarello, Mike Aicher, Lawrence Blatt, and Sumita Pennathur
Founder and CEO: Ron Chiarello
CTO: Johnson Chiang
16 articles about Alveo Technologies
Alveo Technologies and Corteva Agriscience Collaborate to Advance Molecular Crop Disease Diagnostics and Improve Crop Yields
Alveo Technologies, Inc. announced a collaboration with Corteva Agriscience to expand the offering of its novel eco-friendly molecular sensing and disease diagnostics technology to include a first-in-field agricultural disease diagnostic.
Alveo Technologies Announces Partner Program and Portal, New Enablement Software Suite, Further Empowering Partners in Co-Development of Advanced Molecular Diagnostics
Alveo Technologies, Inc., a leader in molecular sensing and diagnostics with its proprietary be.well™ technology platform, launched a web-based partner portal and suite of enablement software tools to further drive innovative partnerships onto the platform to co-develop and commercialize rapid, point of need diagnostic solutions across multiple life sciences industry sectors.
Alveo Technologies, Inc. today announced its quality management system (QMS) has achieved ISO 13485:2016 certification for the design, development and manufacture of in vitro diagnostic kits and analyzers for the detection of infectious disease.
Alveo Technologies and Government of Barbados Collaborate to Co-Develop Advanced Molecular Disease Diagnostics Across Multiple End Markets
Alveo Technologies, Inc. announced it has signed a Memorandum of Understanding with the Barbados Investment and Development Corporation to co-develop on its novel molecular sensing platform, while contributing to the growth of the life sciences industry in the Caribbean nation.
Alveo Technologies, Inc. announced the appointment of three life sciences industry leaders to its senior executive team to advance the development of its novel molecular sensing and diagnostics technology and lead the company through strategic growth and commercialization of its rapid, multiplexed molecular diagnostic platform, be.well™.
Alveo Technologies , Inc., an infectious disease testing leader, announced today biotechnology, diagnostics and medical device executive Neil Gunn has accepted an appointment to its board of directors
Prestigious honor validates potential of Alveo's low-cost, accessible COVID-19 testing technology as company prepares for commercialization
Alveo Technologies, Inc. (Alveo) announced today that it has received its first regulatory approval with the CE (Conformité Européenne) Mark for its be.well™ COVID-19 Flex Test.
9/18/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Alveo Technologies Expands Scientific Advisory Board with Appointment of Esteemed Healthcare Business Executive, Fran Soistman
Alveo Technologies, a leader in developing novel technologies that enable real-time, low-cost, at-home molecular detection of infectious disease, today announced that Fran Soistman has joined the company’s Scientific Advisory Board (SAB)
8/21/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
7/10/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 1, 2020.
Alveo Technologies Announces Research Collaboration with Janssen Pharmaceuticals, Inc. to Advance At-Home Testing Platform for Viral Infectious Diseases
Alveo Technologies , a leader in developing novel technologies that enable real-time, low-cost, at-home molecular detection of infectious disease, announced today that it has entered into a research collaboration with Janssen Pharmaceuticals, Inc., (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to advance Alveo’s be.well™ platform of analyzers, nasal swabs and cartridges for the dete
Alveo Technologies, Inc. has been named Chief Technology Officer and Rixun Fang, Ph.D., has been appointed Director of Assay Development.
The offering proceeds will be used to advance the optimization and commercialization of Alveo's rapid diagnostic platform for infectious diseases.